High Resolution Native Mass Spectrometry in Biopharmaceuticals: From Protein / Ligand Screening to Therapeutic Protein Characterization
CEN Webinars: Stronger Bonds
High Resolution Native Mass Spectrometry in Biopharmaceuticals:
From Protein / Ligand Screening to Therapeutic Protein Characterization
Thursday March 27th 2014
8:00 a.m. PDT / 11:00 a.m. EDT / 15:00 GMT
SPEAKERS
Speaker
Dr. Rebecca Burnley,
Postdoctoral Research Fellow,
UCB (Slough, UK)
 
Speaker
Dr. Sarah Cianfé́rani,
Senior Scientist,
Hubert Curien Pluridisciplinary Institute (CNRS)
Spacer
MODERATOR
Moderator
Britt E. Erickson, Ph.D.,
Senior Editor,
C&EN
Register Now
OVERVIEW

This webinar, in two parts, will cover biopharmaceutical applications of native MS for the determination of diverse characteristics including ligand-binding, non-covalent protein interactions, and intact antibody characterization.

In the first part, Rebecca Burnley will address application of native MS to protein-ligand screening. Topics will include how proper desolvation and high spectral resolution allows more reliable measurement of binding, including weak binding and binding of low MW compounds, analysis of heterogenous proteins, and the capability to screen multiple compounds at once.

In the second part, Sarah Cianfé́rani will focus on the possibilities and limitations of native MS in the characterization of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), determining such critical characteristics as drug to antibody ratio (DAR), mAb/ antigen noncovalent complexes characterization, higher order structure determination, and mAbs mixture analysis.

KEY LEARNING OBJECTIVES

- What is native MS and how can it be useful in drug discovery processe?

- What is the classical native MS-based workflow for protein/ligand and biopharmaceuticals characterization?

- Why use native MS for protein/ligand interaction characterization?

- Why use native MS for therapeutic protein characterization?

- What are the benefits of high resolution native MS for biopharmaceutical characterization?

WHO SHOULD ATTEND
  • Analysts from industry, government and academic laboratories who:
  •  
  • • Work in or are interested in the field of biopharmaceuticals
  •  
  • • Are performing regularly physico-chemical characterization of biopharmaceuticals and protein/ ligand interactions
  •  
  • • Want to learn more about recent trends in native MS for the analysis of protein/ligand systems and monoclonal antibodies
  •  
SPONSOR
Sponsor Logo